Related Experiment Video
Updated: May 26, 2026

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy
Soudeh Ghafouri-Fard1, Mohammad-Hossein Modarressi
1Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran. ghafourifard@razi.tums.ac.ir
Abstract:
Cancer-testis (CT) genes have a restricted expression in normal tissues except testis and a wide range of tumor types. Testis is an immune-privileged site as a result of a blood barrier and lack of HLA class I expression on the surface of germ cells. Hence, if testis-specific genes are expressed in other tissues, they can be immunogenic. Expression of some CT genes in a high percentage of brain tumors makes them potential targets for immunotherapy. In addition, expression of CT genes in cancer stem cells may provide special targets for treatment of cancer recurrences and metastasis. The presence of antibodies against different CT genes in patients with advanced tumors has raised the possibility of polyvalent antitumor vaccine application.
Insights
Cancer-testis (CT) genes, normally found only in testes, can become immunogenic when expressed in tumors. This makes CT genes promising targets for novel cancer vaccines and immunotherapies, particularly for brain tumors and recurring cancers.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Cancer-testis (CT) genes exhibit restricted expression in normal tissues, primarily the testis.
- The testis is an immune-privileged site, shielding germ cells from immune surveillance.
- Aberrant expression of CT genes in tumors can render them immunogenic, presenting therapeutic opportunities.
Purpose of the Study:
- To explore the potential of cancer-testis (CT) genes as targets for cancer immunotherapy.
- To investigate the role of CT gene expression in brain tumors and cancer stem cells.
- To evaluate the feasibility of polyvalent antitumor vaccines based on CT gene antibodies.
Main Methods:
- Analysis of CT gene expression patterns in normal tissues and various tumor types.
- Assessment of CT gene expression in brain tumors and cancer stem cells.
- Review of existing data on antibodies against CT genes in cancer patients.
Main Results:
- CT genes are expressed in a significant proportion of brain tumors, indicating potential immunotherapeutic targets.
- CT gene expression in cancer stem cells suggests a role in tumor recurrence and metastasis.
- Antibodies against CT genes are present in patients with advanced cancers, supporting vaccine development.
Conclusions:
- Cancer-testis genes represent promising targets for developing novel immunotherapies and vaccines against various cancers.
- Targeting CT genes in brain tumors and cancer stem cells could offer new treatment strategies for difficult-to-treat malignancies.
- The presence of anti-CT gene antibodies supports the potential of polyvalent vaccines for broad antitumor efficacy.
Related Concept Videos
Tumor Immunotherapy
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

